CY71 Stock Overview
A biotechnology company, develops therapies and vaccines that are focused on critical unmet needs in oncology. More details
| Snowflake Score | |
|---|---|
| Valuation | 0/6 |
| Future Growth | 0/6 |
| Past Performance | 0/6 |
| Financial Health | 6/6 |
| Dividends | 0/6 |
Community vs My Fair Value
Create NarrativeSelect a narrative for quick price alerts from the community, or create your own.
Anixa Biosciences, Inc. Competitors
Price History & Performance
| Historical stock prices | |
|---|---|
| Current Share Price | US$2.28 |
| 52 Week High | US$3.62 |
| 52 Week Low | US$2.02 |
| Beta | 0.43 |
| 1 Month Change | -1.72% |
| 3 Month Change | -28.30% |
| 1 Year Change | -14.93% |
| 3 Year Change | -25.54% |
| 5 Year Change | 28.81% |
| Change since IPO | -37.36% |
Recent News & Updates
Recent updates
Shareholder Returns
| CY71 | DE Biotechs | DE Market | |
|---|---|---|---|
| 7D | -6.6% | 0.6% | 1.7% |
| 1Y | -14.9% | -12.2% | 12.8% |
Return vs Industry: CY71 underperformed the German Biotechs industry which returned -13.8% over the past year.
Return vs Market: CY71 underperformed the German Market which returned 13.4% over the past year.
Price Volatility
| CY71 volatility | |
|---|---|
| CY71 Average Weekly Movement | 9.9% |
| Biotechs Industry Average Movement | 5.9% |
| Market Average Movement | 6.3% |
| 10% most volatile stocks in DE Market | 13.0% |
| 10% least volatile stocks in DE Market | 3.1% |
Stable Share Price: CY71's share price has been volatile over the past 3 months compared to the German market.
Volatility Over Time: CY71's weekly volatility (10%) has been stable over the past year, but is still higher than 75% of German stocks.
About the Company
| Founded | Employees | CEO | Website |
|---|---|---|---|
| 1982 | 5 | Amit Kumar | www.anixa.com |
Anixa Biosciences, Inc., a biotechnology company, develops therapies and vaccines that are focused on critical unmet needs in oncology. Its therapeutics programs include the development of a chimeric endocrine receptor-T cell therapy, a novel form of chimeric antigen receptor-T cell (CAR-T) technology that is focused on treating ovarian cancer. The company’s vaccine programs include the development of a vaccine against breast cancer, initially focused on triple negative breast cancer (TNBC), the most lethal form of breast cancer; and the development of a vaccine against ovarian cancer, as well as a vaccine discovery program to develop additional cancer vaccines to address intractable cancers, including high incidence malignancies in lung, colon, and prostate.
Anixa Biosciences, Inc. Fundamentals Summary
| CY71 fundamental statistics | |
|---|---|
| Market cap | €74.85m |
| Earnings (TTM) | -€11.03m |
| Revenue (TTM) | n/a |
0.0x
P/S Ratio-6.7x
P/E RatioIs CY71 overvalued?
See Fair Value and valuation analysisEarnings & Revenue
| CY71 income statement (TTM) | |
|---|---|
| Revenue | US$0 |
| Cost of Revenue | US$0 |
| Gross Profit | US$0 |
| Other Expenses | US$12.48m |
| Earnings | -US$12.48m |
Last Reported Earnings
Jan 31, 2025
Next Earnings Date
n/a
| Earnings per share (EPS) | -0.39 |
| Gross Margin | 0.00% |
| Net Profit Margin | 0.00% |
| Debt/Equity Ratio | 0% |
How did CY71 perform over the long term?
See historical performance and comparisonCompany Analysis and Financial Data Status
| Data | Last Updated (UTC time) |
|---|---|
| Company Analysis | 2025/05/07 19:25 |
| End of Day Share Price | 2025/05/07 00:00 |
| Earnings | 2025/01/31 |
| Annual Earnings | 2024/10/31 |
Data Sources
The data used in our company analysis is from S&P Global Market Intelligence LLC. The following data is used in our analysis model to generate this report. Data is normalised which can introduce a delay from the source being available.
| Package | Data | Timeframe | Example US Source * |
|---|---|---|---|
| Company Financials | 10 years |
| |
| Analyst Consensus Estimates | +3 years |
|
|
| Market Prices | 30 years |
| |
| Ownership | 10 years |
| |
| Management | 10 years |
| |
| Key Developments | 10 years |
|
* Example for US securities, for non-US equivalent regulatory forms and sources are used.
Unless specified all financial data is based on a yearly period but updated quarterly. This is known as Trailing Twelve Month (TTM) or Last Twelve Month (LTM) Data. Learn more.
Analysis Model and Snowflake
Details of the analysis model used to generate this report is available on our Github page, we also have guides on how to use our reports and tutorials on Youtube.
Learn about the world class team who designed and built the Simply Wall St analysis model.
Industry and Sector Metrics
Our industry and section metrics are calculated every 6 hours by Simply Wall St, details of our process are available on Github.
Analyst Sources
Anixa Biosciences, Inc. is covered by 5 analysts. 3 of those analysts submitted the estimates of revenue or earnings used as inputs to our report. Analysts submissions are updated throughout the day.
| Analyst | Institution |
|---|---|
| Andrew D'Silva | B. Riley Securities, Inc. |
| Jason Kolbert | D. Boral Capital LLC. |
| Yi Chen | H.C. Wainwright & Co. |